Dixon Hubard Feinour & Brown Inc. VA decreased its stake in shares of Intrexon Corporation (NYSE:XON) by 1.0% during the second quarter, Holdings Channel reports. The firm owned 70,604 shares of the biotechnology company’s stock after selling 745 shares during the period. Dixon Hubard Feinour & Brown Inc. VA’s holdings in Intrexon Corporation were worth $1,701,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Intrexon Corporation during the fourth quarter valued at approximately $17,300,000. State Street Corp increased its position in shares of Intrexon Corporation by 34.0% in the first quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock valued at $53,664,000 after buying an additional 687,406 shares during the period. Vanguard Group Inc. increased its position in shares of Intrexon Corporation by 5.6% in the first quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock valued at $84,954,000 after buying an additional 226,090 shares during the period. Capital Advisors Inc. OK purchased a new position in shares of Intrexon Corporation during the first quarter valued at approximately $3,193,000. Finally, First Trust Advisors LP increased its position in shares of Intrexon Corporation by 15.9% in the first quarter. First Trust Advisors LP now owns 1,160,308 shares of the biotechnology company’s stock valued at $22,997,000 after buying an additional 158,964 shares during the period. 84.44% of the stock is owned by hedge funds and other institutional investors.
Intrexon Corporation (NYSE:XON) traded down 1.30% during trading on Monday, reaching $22.83. 564,708 shares of the company were exchanged. The stock’s market capitalization is $2.73 billion. Intrexon Corporation has a 1-year low of $18.41 and a 1-year high of $32.90. The company’s 50-day moving average price is $23.27 and its 200-day moving average price is $22.60.
Intrexon Corporation (NYSE:XON) last announced its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.04. Intrexon Corporation had a negative net margin of 76.32% and a negative return on equity of 21.19%. The company had revenue of $53.70 million for the quarter, compared to the consensus estimate of $49.08 million. During the same quarter in the previous year, the business earned ($0.55) EPS. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. On average, equities analysts forecast that Intrexon Corporation will post ($0.91) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Dixon Hubard Feinour & Brown Inc. VA Cuts Position in Intrexon Corporation (XON)” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2723728/dixon-hubard-feinour-brown-inc-va-cuts-position-in-intrexon-corporation-xon.html.
XON has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, May 2nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $57.00 price objective on shares of Intrexon Corporation in a research note on Tuesday, April 4th. Finally, BidaskClub raised shares of Intrexon Corporation from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $40.96.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corporation (NYSE:XON).
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.